Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:DNTH NASDAQ:INDV NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$52.38-2.2%$52.41$33.03▼$78.48$5.05B1.751.89 million shs3.10 million shsDNTHDianthus Therapeutics$90.24+1.0%$78.79$16.64▼$96.50$4.91B1.18942,491 shs343,810 shsINDVIndivior$39.59+1.6%$31.95$10.63▼$40.02$4.83B0.92.37 million shs2.76 million shsMLTXMoonLake Immunotherapeutics$17.01-3.1%$17.51$5.95▼$62.75$1.22B1.011.72 million shs699,621 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+1.26%+4.28%-0.71%+34.98%DNTHDianthus Therapeutics0.00%+0.30%+1.65%+66.64%+302.86%INDVIndivior0.00%+9.76%+23.60%+6.23%+214.36%MLTXMoonLake Immunotherapeutics0.00%-0.71%-3.63%+8.85%-60.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$52.38-2.2%$52.41$33.03▼$78.48$5.05B1.751.89 million shs3.10 million shsDNTHDianthus Therapeutics$90.24+1.0%$78.79$16.64▼$96.50$4.91B1.18942,491 shs343,810 shsINDVIndivior$39.59+1.6%$31.95$10.63▼$40.02$4.83B0.92.37 million shs2.76 million shsMLTXMoonLake Immunotherapeutics$17.01-3.1%$17.51$5.95▼$62.75$1.22B1.011.72 million shs699,621 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+1.26%+4.28%-0.71%+34.98%DNTHDianthus Therapeutics0.00%+0.30%+1.65%+66.64%+302.86%INDVIndivior0.00%+9.76%+23.60%+6.23%+214.36%MLTXMoonLake Immunotherapeutics0.00%-0.71%-3.63%+8.85%-60.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$64.5323.19% UpsideDNTHDianthus Therapeutics 3.00Buy$115.5528.04% UpsideINDVIndivior 3.00Buy$39.33-0.65% DownsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.0835.67% UpsideCurrent Analyst Ratings BreakdownLatest MLTX, CRSP, DNTH, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNTHDianthus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$98.004/8/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/30/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/25/2026CRSPCRISPR Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/23/2026MLTXMoonLake Immunotherapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$12.00 ➝ $24.003/19/2026DNTHDianthus Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$135.003/19/2026MLTXMoonLake Immunotherapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $40.003/17/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/17/2026CRSPCRISPR Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.00 ➝ $110.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR TherapeuticsN/AN/AN/AN/A$20.17 per shareN/ADNTHDianthus Therapeutics$2.04M2,413.30N/AN/A$11.41 per share7.91INDVIndivior$1.24B3.90$2.86 per share13.85($0.78) per share-50.76MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.52N/AN/AN/A-16,569.77%-26.31%-22.30%5/11/2026 (Estimated)DNTHDianthus Therapeutics-$162.34M-$4.10N/AN/AN/A-7,973.33%-38.85%-36.42%5/5/2026 (Estimated)INDVIndivior$210M$1.9520.3011.89N/A19.44%-219.26%29.40%N/AMLTXMoonLake Immunotherapeutics-$227.32M-$3.52N/AN/AN/AN/A-66.56%-50.23%5/11/2026 (Estimated)Latest MLTX, CRSP, DNTH, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CRSPCRISPR Therapeutics-$1.2227-$1.28-$0.0573-$1.28$6.06 million$1.46 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.1029-$0.85+$0.2529-$0.85$0.40 million$0.46 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/A2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A13.3213.32DNTHDianthus TherapeuticsN/A13.3213.32INDVIndiviorN/A0.860.66MLTXMoonLake Immunotherapeutics0.249.279.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%DNTHDianthus Therapeutics47.53%INDVIndivior60.33%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%DNTHDianthus Therapeutics3.02%INDVIndivior0.74%MLTXMoonLake Immunotherapeutics12.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.43 million92.48 millionOptionableDNTHDianthus Therapeutics8054.45 million52.81 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableMLTXMoonLake Immunotherapeutics271.73 million63.09 millionOptionableMLTX, CRSP, DNTH, and INDV HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics (MLTX) to Release Earnings on MondayMay 4 at 10:22 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from BrokeragesMay 2 at 2:37 AM | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from BrokeragesMay 2 at 2:34 AM | marketbeat.comShort Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2%May 1, 2026 | marketbeat.comThe CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?April 18, 2026 | fool.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $945,644.79 in StockApril 15, 2026 | insidertrades.comMajor Insider Move at MoonLake Immunotherapeutics Stirs Investor AttentionApril 14, 2026 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 SharesApril 14, 2026 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 SharesApril 14, 2026 | marketbeat.comPositive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake ImmunotherapeuticsApril 14, 2026 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6% - Here's WhyApril 10, 2026 | marketbeat.comJPMorgan Chase & Co. Buys 134,764 Shares of MoonLake Immunotherapeutics $MLTXApril 10, 2026 | marketbeat.comBiotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesApril 7, 2026 | fool.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from AnalystsApril 7, 2026 | marketbeat.comHow Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis SuppurativaApril 5, 2026 | finance.yahoo.comInsider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 3,750,000 Shares of StockApril 3, 2026 | insidertrades.comMajor Insider Move at MoonLake Immunotherapeutics Shakes Up Investor SentimentApril 2, 2026 | tipranks.comWhy MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 7.24%April 2, 2026 | aaii.comAMoonLake ImmunotherapeuticsApril 1, 2026 | marketwatch.comH.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)March 31, 2026 | theglobeandmail.comMLTX stock garners retail attention on buyout speculation, positive skin condition trial dataMarch 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026MLTX, CRSP, DNTH, and INDV Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$52.38 -1.20 (-2.24%) Closing price 04:00 PM EasternExtended Trading$52.11 -0.27 (-0.52%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Dianthus Therapeutics NASDAQ:DNTH$90.24 +0.90 (+1.01%) Closing price 04:00 PM EasternExtended Trading$90.18 -0.05 (-0.06%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Indivior NASDAQ:INDV$39.59 +0.61 (+1.56%) Closing price 04:00 PM EasternExtended Trading$39.05 -0.54 (-1.36%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.MoonLake Immunotherapeutics NASDAQ:MLTX$17.01 -0.55 (-3.13%) Closing price 04:00 PM EasternExtended Trading$16.96 -0.05 (-0.29%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
